Albendazole - Medication and Pregnancy KB

Albendazole

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Celik, 2018	Turkey 2015 - 2017	Pregnant patients diagnosed with hydatid disease (HD) during the course of their pregnancy.	Pregnant patients treated with albendazole following diagnosis of hydatid disease (HD) (without surgery).	unexposed, sick Pregnant patients without treatment for hydatid disease (HD) (neither albendazole, nor surgery, nor percutaneous aspiration-irrigation and re-aspiration).	1 / 18
Choi, 2017	South Korea Not specified	Pregnant women undergoing teratogenic risk counselling at the hospital.	Pregnant women who were inadvertently exposed to albendazole in the first trimester of pregnancy (single dose of 200 or 400 mg).	unexposed, disease free Pregnant women who were not exposed to any medication.	124 / 382
Gyapong, 2003	Ghana Not specified	All women of childbearing age (15–45 years) in the Ahanta-West District of the Western Region of Ghana, as well as all infants born to these mothers within 42 weeks of the period following the treatment.	Inadvertent exposure to albendazole and ivermectin drugs in early pregnancy.	unexposed, sick No exposure to albendazole and ivermectin drugs in early pregnancy.	50 / 293
Mpairwe (Controls exposed to Praziquantel), 2011	Uganda 2003 - 2005	Pregnant women in their second or third trimester, resident in the study area, planning delivery at Entebbe Hospital, willing to participate and willing to know their HIV status.	Pregnant women receiving a single dose of oral albendazole (400 mg) and placebo.	exposed to other treatment, sick Pregnant women receiving a single dose of Praziquantel (40 mg/kg) and placebo.	625 / 628	(Ndibazza 2010 ; Webb 2011 and Mpairwe 2011 => same placebo-controlled, with different outcomes, except for Stillbirths (overlapping) for which the data provided by Ndibazza 2010 was reported (rather than Mpairwe 2011) because these data were adjusted.
Mpairwe (Controls unexposed, sick), 2011	Uganda 2003 - 2005	Pregnant women in their second or third trimester, resident in the study area, planning delivery at Entebbe Hospital, willing to participate and willing to know their HIV status.	Pregnant women receiving a single dose of oral albendazole (400 mg) and placebo.	unexposed, sick Pregnant women receiving placebo and placebo.	625 / 628	(Ndibazza 2010 ; Webb 2011 and Mpairwe 2011 => same placebo-controlled, with different outcomes, except for Stillbirths (overlapping) for which the data provided by Ndibazza 2010 was reported (rather than Mpairwe 2011) because these data were adjusted.
Ndibazza (Controls exposed to praziquantel), 2010	Uganda 2003 - 2005	Women were eligible if they were healthy on recruitment day, a resident in the study area, planning to deliver at the hospital, willing to know their HIV status, prepared to participate in the study, and in their second or third trimester (based on last menstrual period and midwife's assessment).	Pregnant women receiving oral albendazole (400 mg) and placebo in their second or third trimester.	exposed to other treatment, sick Pregnant women receiving praziquantel and placebo in their second or third trimester.	625 / 626	Study on the efficacy of azole in an obstetrical indication, including the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here.
Ndibazza (Controls unexposed, sick), 2010	Uganda 2003 - 2005	Women were eligible if they were healthy on recruitment day, a resident in the study area, planning to deliver at the hospital, willing to know their HIV status, prepared to participate in the study, and in their second or third trimester (based on last menstrual period and midwife's assessment).	Pregnant women receiving oral albendazole (400 mg) and placebo in their second or third trimester.	unexposed, sick Pregnant women receiving placebo and placebo in their second or third trimester.	625 / 628	Study on the efficacy of azole in an obstetrical indication, including the intrauterine deaths and/or late pregnancy and/or neonatal outcomes that are studied as efficacy criteria rather than safety one. => Not reported here.
Ndyomugyenyi (Controls exposed to ivermectin), 2008	Uganda 2003 - 2005	Pregnant women of any parity attending antenatal care (ANC) in their second trimester (> 16 weeks of gestation at first ANC booking) at a public health center (type 4).	Women infected with any intestinal helminth receiving albendazole administered as a single dose of 400 mg.	exposed to other treatment, sick Women infected with any intestinal helminth receiving ivermectin administered according to height.	160 / 170	Ndibazza 2010 and Ndyomugyenyi 2008: 2 clinical trials not conducted in the same districts: Entebbe municipality and Masindi district=> different data.
Ndyomugyenyi (Controls unexposed, disease free), 2008	Uganda 2003 - 2005	Pregnant women of any parity attending antenatal care (ANC) in their second trimester (> 16 weeks of gestation at first ANC booking) at a public health center (type 4).	Women infected with any intestinal helminth receiving albendazole administered as a single dose of 400 mg.	unexposed, disease free Pregnant women without soil-transmitted helminths (STHs).	160 / 207	Ndibazza 2010 and Ndyomugyenyi 2008: 2 clinical trials not conducted in the same districts: Entebbe municipality and Masindi district=> different data.

Case-control studies (cohort)

Study	Country Study period	Case	Control	Sample size	Rmk

Warning! There are no case-control studies available for this drug.

master protocol